AxoGen Inc
NASDAQ:AXGN
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
Market Cap | EV/FCFF | ||||
---|---|---|---|---|---|
US |
AxoGen Inc
NASDAQ:AXGN
|
256.4m USD | -12.8 | ||
US |
Abbott Laboratories
NYSE:ABT
|
181.5B USD | 38.1 | ||
US |
Intuitive Surgical Inc
NASDAQ:ISRG
|
135.1B USD | 218.5 | ||
US |
Stryker Corp
NYSE:SYK
|
125.2B USD | 46.7 | ||
IE |
Medtronic PLC
NYSE:MDT
|
108.3B USD | 25.4 | ||
US |
Boston Scientific Corp
NYSE:BSX
|
107.4B USD | 67.5 | ||
US |
Becton Dickinson and Co
NYSE:BDX
|
67.6B USD | 30.4 | ||
DE |
Siemens Healthineers AG
XETRA:SHL
|
57.9B EUR | 42.7 | ||
US |
Edwards Lifesciences Corp
NYSE:EW
|
51.2B USD | 79.6 | ||
CN |
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
368.6B CNY | 33 | ||
US |
Dexcom Inc
NASDAQ:DXCM
|
50.9B USD | 86.5 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.